Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically ill patients hospitalized for COVID-19
Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically ill patients hospitalized for COVID-19
DD01 is a long-acting dual agonist of glucagon-like peptide-1 and glucagon receptors.
Adding the radionuclide therapy ¹⁷⁷Lu-PSMA-617 to enzalutamide improved outcomes in patients with treatment-naïve mCRPC in a phase 2 trial.
Investigators assessed the monosodium urate burden using 2 ultrasound scoring systems among patients with gout and compared their ability to predict flares.
Even after adjusting for socioeconomic factors, environmental factors independently tied to higher risk
US cancer survivors are more likely than the general population to have a mobility or self-care disability, a large study suggests.
Incorporating the chemokines in a model strongly detected clinically relevant rejections warranting biopsy and, if confirmed, antirejection treatment.
Findings are based on a study of 88 men and 78 women with ANCA-associated vasculitis with glomerulonephritis and severe kidney disease at diagnosis.
Researchers conducted an economic evaluation to assess the sustainable cost-based prices vs market prices for insulin and antidiabetic drugs.
Issues include explainability, patient consent, and responsibility
Researchers conducted a post hoc analysis to assess the effect of calcium and vitamin D supplementation on mortality among postmenopausal women.